1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,700 | 12,900 | 05.09. | |
| 12,400 | 13,200 | 05.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 3 | Investing.com | ||
| 14.08. | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08. | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 111 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
| 15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
| 15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
| 15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 5 | Investing.com Deutsch | ||
| 14.07. | William Blair stuft MiNK-Therapeutics-Aktie nach 700-%-Rallye herab | 8 | Investing.com Deutsch | ||
| 14.07. | William Blair downgrades MiNK Therapeutics stock to Market Perform after 700% surge | 3 | Investing.com | ||
| 14.07. | MiNK Therapeutics stock maintains Buy rating at H.C. Wainwright after case study publication | 1 | Investing.com | ||
| 14.07. | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.07. | MiNK Therapeutics stock falls after William Blair downgrade | 4 | Investing.com | ||
| 14.07. | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 292 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.07. | Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? | 11 | Benzinga.com | ||
| 11.07. | MiNK Therapeutics Stock Skyrockets 643% On Cancer Remission Case | 4 | RTTNews | ||
| 11.07. | Durchbruch in der Krebstherapie: Aktie von MiNK Therapeutics schießt um 200 % in die Höhe | 47 | Investing.com Deutsch | ||
| 11.07. | MiNK Therapeutics stock soars after cancer remission breakthrough | 8 | Investing.com | ||
| 11.07. | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer | 125 | GlobeNewswire (Europe) | NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 36,400 | +0,41 % | EQS-PVR: BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,090 | +0,28 % | Down 34%, Should You Buy the Dip on Viking Therapeutics? | ||
| NOVOCURE | 10,350 | -1,19 % | Novocure skizziert auf Wells Fargo Konferenz Expansionsstrategie in der Krebstherapie | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,884 | -0,53 % | Oxford Nanopore price target raised to GBP1.90 from GBP1.50 at Piper Sandler | ||
| MEREO BIOPHARMA | 1,465 | -3,30 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| BIOLINERX | 2,790 | -2,96 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ASSERTIO | 0,798 | -1,18 % | American Society of Radiologic Technologists: ASRT Launches Phase Two of the Be Seen Campaign | ALBUQUERQUE, NEW MEXICO / ACCESS Newswire / June 23, 2025 / The American Society of Radiologic Technologists has launched the second phase of its Be Seen public awareness campaign.ASRT Be Seen Campaign... ► Artikel lesen | |
| ROIVANT SCIENCES | 11,000 | -0,23 % | Roivant Sciences Ltd. - 8-K, Current Report | ||
| APPLIED THERAPEUTICS | 0,413 | +2,03 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen | |
| AKERO THERAPEUTICS | 38,340 | +0,47 % | Akero Therapeutics stock initiated with Buy rating at H.C. Wainwright | ||
| ARVINAS | 7,830 | +2,89 % | Arvinas Inc.: Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | - Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant - -... ► Artikel lesen | |
| REVOLUTION MEDICINES | 34,200 | -1,16 % | Revolution Medicines stock initiated with Buy rating at Truist Securities | ||
| JANUX THERAPEUTICS | 23,990 | +0,21 % | Guggenheim initiates Janux Therapeutics stock with Buy rating on PSMA therapy | ||
| WEREWOLF THERAPEUTICS | 1,355 | +0,37 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | - WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 10,970 | +4,48 % | Transcode Therapeutics, Inc. - 8-K, Current Report |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,69 % bei einem Aktienkurs von 12,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.